Healthcare
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Name
Novo
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 11in the latest 22
Mood and coverage · last 7 days
Market chart- Novo · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Sun, Oct 11 | — | 0 |
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
Latest on Novo
Newest firstHealthcare
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
Healthcare
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Healthcare
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.
Healthcare
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring
Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billio…
Novo defends diversification push as CEO eyes deals beyond obesity
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
Markets
Stocks making the biggest moves premarket: Paramount, Warner Bros., Accenture, Novo & more
These are the stocks posting the largest moves premarket.
Healthcare
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
Healthcare
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
Housing
'Trust but verify:' How Novo Construction compares drawing packages with AI
Colin Stoner, chief information officer for Novo Construction, describes the time saved in comparing drawings, a traditionally tedious process, with a new tool.
Healthcare
Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant
Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani's NanoPortal platform for chronic weight management. Viva…
Healthcare
Can Novo Nordisk (CPSE:NOVO B) Stay Cheap As GLP 1 Access Expands?
Novo Nordisk stock has pulled back sharply over the past year, yet the shares still screen as undervalued on earnings. This sets up a clear tension between rec…
Commodities
Sponsored: Novo's Belltopper resource starts small, aims bigger
Novo Resources Executive Co-Chairman Michael Spreadborough in conversation with The Northern Miner video host Devan Murugan. This sponsored video is PROMOTED C…
Healthcare
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
Healthcare
Hims & Hers falls 8% after Novo's legal threat. Here's the latest
Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal"
Finance
Industrial Loan Charters Take Center Stage as De Novo Banking Makes a Comeback
Treasury Secretary Scott Bessent used his House testimony Wednesday (Feb. 4) to spotlight an urgency for new bank formation. More than half of community
Finance
Industrial Loan Charters Emerge as Go-to Path for De Novo Banking
Treasury Secretary Scott Bessent used his House testimony Wednesday (Feb. 4) to spotlight an urgency for new bank formation. More than half of community
Healthcare
Novo's next-gen obesity drug shows positive results, heads to late-stage testing
Novo Nordisk said its experimental drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes.
Healthcare
Novo chops Wegovy prices, but doctors still see affordability challenges for patients
Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insura…
Healthcare
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.
Healthcare
Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%
Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around af…
Healthcare
FDA approves Hikma's generic version of Novo's diabetes drug Victoza
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer's permission.
